shares jumped more than 11% in after-hours action Tuesday as the data-management software developer posted sharply higher earnings for the first fiscal quarter. The Fremont, Calif., small-cap reported $1.6 million, or 45 cents a share, in income from continuing operations, compared with last year's $789,000, or 23 cents a share. Sales reached $5.2 million, an 11% climb from a year ago. Shares were adding $1.89 to $18.60 in recent trading.
, a footwear maker based in Goleta, Calif., was higher on a profit of $23.5 million, or $1.82 a share, in the fourth quarter (excluding a noncash pretax impairment charge estimated between $14 million and $16 million) on sales that surged 36.7% year over year to $124.4 million. Year-ago earnings were $12.1 million, or 94 cents a share. Analysts surveyed by Thomson Financial had sought $1.31 a share on $110.7 million revenue.
Looking ahead, the company expects to see 15% growth in 2007 revenue and 5% income growth. That translates to $3.47 a share on $350.1 million, based on 2006 sales figures, which top the mean by 36 cents and $11 million, respectively. Shares were up $3.51, or 5.7%, to $64.96.
Human Genome Sciences
rose on two pieces of good news. Fourth-quarter results were impressive, as the drugmaker narrowed its losses to $48.5 million, or 36 cents a share, compared with last year's downside of $69.5 million, or 53 cents a share. Analysts were expecting a loss of 44 cents a share. Revenue added 8% to $10 million, which was $2.3 million above consensus. The Rockville, Md., company also expects 2007 revenue to surge 50% year over year to $38.7 million, ahead of the $35.6 million targets.
Human Genome also said it has begun dosing in a late-phase trial of its hepatitis C treatment Albuferon, in combination with ribavirin, on strong interim results from a phase IIb study. Swiss drugmaker
is developing the product with Human Genome. The latter was up 27 cents, or 2.5%, to $11.23. Novartis shares were recently adding 18 cents to $55.50.
was higher after the San Jose, Calif,-based maker of data-storage disks said it will supply disk-drive maker
with aluminum substrates in addition to its existing media supply agreement. Komag shares were rising 69 cents, or 2.1%, to $33.50. Seagate stock was unchanged.
, which develops software for fonts, browsing and publishing, slid on disappointing fourth-quarter results. The Cambridge, Mass., company whittled its fourth-quarter profit down to $630,000, or 6 cents a share, from last year's $788,000, or 8 cents a share. Revenue was up 20% to $5.5 million. Shares were losing $1.38, or 13.4%, to $8.89.
widened its fourth-quarter losses to $15.9 million, or 8 cents a share, from $2.1 million, or a penny a share, a year ago. The Santa Clara, Calif., semiconductor company's sales plummeted to $2.4 million from $13.3 million last year. Two analysts were looking for 6-cent losses on $3 million in revenue. Shares were dropping 6 cents, or 7.2%, to 81 cents.
fell after the San Rafael, Calif., technical-software company announced it will restate its financials downward from fiscal years 2003 through 2006, having completed its stock-option grant investigation. The company estimates pretax, noncash charges will range between $38 million and $45 million for stock-option expenses over the past 18 years, with an estimated $23 million to $26 million contained in the 2003-06 period. The remainder will be recorded for year-end 2002. Shares were down $2.35, or 5.8%, to $38.45.